PREP

What can we help you find?
[[thumbnail_alt_text]]
The study, called DELIVER: A Phase 3b Safety Study of the Dapivirine Ring and PrEP in Pregnant Women, will complement an ongoing NIH-funded trial of PrEP in adolescents and young women during pregnancy and the first 6 months after birth.
[[thumbnail_alt_text]]
A study funded by the National Institutes of Health (NIH) found that despite similar rates of enrollment into medical care, youth with HIV have much lower rates of viral suppression compared with adults. 
 
[[thumbnail_alt_text]]
Researchers from George Washington University have shown that the human apolipoprotein A-I binding protein (AIBP) is capable of inhibiting HIV replication by targeting lipid rafts and reducing virus-cell fusion.
[[thumbnail_alt_text]]
Decreased PrEP usage was reportedly due to reduced awareness of prevention strategies, and engagement in health-promoting behaviors.
[[thumbnail_alt_text]]
Top news from across the health care landscape.
[[thumbnail_alt_text]]
A study found that an injection of neutralizing antibodies is associated with enhanced T cell response that specifically recognizes HIV.
 
[[thumbnail_alt_text]]
The mechanism behind HIV resistance affects the ability of integrase strand transfer inhibitors to bind and block the HIV enzyme integrase.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
[[thumbnail_alt_text]]
Robust data show the efficacy of tenofovir disoproxil fumarate with emtricitabine for pre-exposure prophylaxis in all priority populations with a risk for HIV.   
[[thumbnail_alt_text]]
Opioid agonist therapy (OAT) must be widely disseminated and increased in Ukraine in order to optimize HIV prevention and treatment goals, according to a recent study published in The Lancet.
[[thumbnail_alt_text]]
Antiretroviral therapy may not be entirely effective in restoring the immune protection resulting from viral infections or childhood vaccines received prior to becoming HIV-positive.
 
[[thumbnail_alt_text]]
The findings support the inclusion of these patient populations in ICI-based clinical trials and treatment.